Lynparza Tablets 100mg, 150mg CEI, Investigation on Development of Bone Marrow Depression in Patients With Unresectable or Recurrent BRCA Mutated HER2 Negative Breast Cancer Who Have Previously Received Anticancer Chemotherapy
Phase of Trial: Phase IV
Latest Information Update: 18 Feb 2019
At a glance
- Drugs Olaparib (Primary)
- Indications Advanced breast cancer; Male breast cancer
- Focus Adverse reactions
- Sponsors AstraZeneca
- 24 Aug 2018 Status changed from not yet recruiting to recruiting.
- 03 Aug 2018 Planned initiation date changed from 23 Jul 2018 to 31 Aug 2018.
- 24 Jul 2018 New trial record